SCHEMBL3174166

SCHEMBL3174166

CC(C)(C)NC(=O)N1CCCC1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
HSD17B10 Q99714 2/20 0.55
CYP2C19 P33261 1/20 0.55
ITGB3 P05106 1/20 0.51
ITGB1 P05556 1/20 0.51
ITGAV P06756 1/20 0.51
ITGA5 P08648 1/20 0.51
ITGA4 P13612 1/20 0.51
THRB P10828 1/20 0.50
ALOX12 P18054 1/20 0.50
KMT2A Q03164 1/20 0.50
ACE P12821 8/20 0.47
REN P00797 4/20 0.47
F2 P00734 2/20 0.47
KDM4E B2RXH2 1/20 0.47
LTA4H P09960 1/20 0.47
MAPT P10636 1/20 0.47
PEPD P12955 1/20 0.47
ALOX15 P16050 1/20 0.47
PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898833 1.00 LMNA (0.55) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL7252378 0.91 LMNA (0.54) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL7680333 0.86 LMNA (0.46) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL7680329 0.84 LMNA (0.44) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL22455535 0.84 F2 (0.49) LMNAHSD17B10CYP2C19F2KDM4E
SCHEMBL7340210 0.83 POLB (0.59) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL3966373 0.81 ITGB3 (0.54) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL18676315 0.81 ITGB3 (0.54) LMNAHSD17B10CYP2C19ITGB3ITGB1
Hydrochloric Acid SCHEMBL7104149 0.80 ITGB3 (0.52) LMNAHSD17B10CYP2C19ITGB3ITGB1
SCHEMBL5134719 0.80 ACE (0.57) LMNAHSD17B10CYP2C19ITGB3ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
CN-102119047-A Heteroaryl derivatives as DGAT1 inhibitors NOVARTIS AG 2011-07-06 CN disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 LMNA 4089/4885HSD17B10 32/4885CYP2C19 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.